Vertex Pharmaceuticals (NASDAQ:VRTX) and WuXi Biologics announced a major license and research service agreement on Monday, February 2, 2026, aimed at developing an innovative trispecific T-cell Engager (TCE) for B-cell mediated autoimmune diseases.
The deal marks a significant expansion of Vertex's portfolio into the "next-generation" immunotherapy space, targeting conditions where current treatments fall short.
Under the terms of the agreement, Vertex receives an exclusive global license to develop and commercialize the preclinical trispecific TCE.
While specific financial breakdowns for this individual asset were not disclosed, WuXi Biologics indicated that this collaboration is part of a broader research platform initiative projected to generate more than $2.3 billion in total potential payments.
WuXi Biologics will receive an upfront payment and is eligible for substantial development, regulatory, and sales milestones, as well as tiered royalties on future net sales.
The trispecific molecule, discovered using WuXi Biologics' proprietary WuXiBody™ platform, is designed to simultaneously bind to three distinct targets (likely CD19, CD20, and CD3) to more effectively deplete the autoreactive B-cells responsible for autoimmune flare-ups.
Beyond the lead asset, the partnership includes a service agreement where WuXi Biologics will provide contract R&D to help Vertex discover and optimize additional next-generation TCEs.